RUBIUS THERAPEUTICS INC (RUBY)
US78116T1034 - Common Stock
ChartMill assigns a Buy % Consensus number of 46% to RUBY. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is 1128.92% above the current price.
RUBY was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about RUBY.
In the previous month the buy percentage consensus was at a similar level.
RUBY was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-09-13 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-09-09 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-09 | SVB Leerink | Maintains | Market Perform |
| 2022-05-11 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-05-11 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-10 | SVB Leerink | Maintains | Market Perform |
| 2022-04-11 | Guggenheim | Maintains | Buy |
| 2022-04-11 | SVB Leerink | Maintains | Market Perform |
| 2022-04-11 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-04-11 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-25 | SVB Leerink | Maintains | Market Perform |
| 2021-11-09 | SVB Leerink | Maintains | Market Perform |
| 2021-05-18 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-04-19 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-03-15 | SVB Leerink | Maintains | Market Perform |
| 2021-03-15 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-23 | SVB Leerink | Maintains | Market Perform |